These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311 [TBL] [Abstract][Full Text] [Related]
23. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652 [TBL] [Abstract][Full Text] [Related]
24. Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility. Calmasini FB; Alexandre EC; Silva FH; De Nucci G; Antunes E; D'Ancona CA; Mónica FZ Urology; 2016 Aug; 94():312.e9-312.e15. PubMed ID: 27131967 [TBL] [Abstract][Full Text] [Related]
25. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020 [TBL] [Abstract][Full Text] [Related]
26. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra. Toque HA; Antunes E; Teixeira CE; De Nucci G Urology; 2008 Sep; 72(3):711-5. PubMed ID: 18359064 [TBL] [Abstract][Full Text] [Related]
27. A cell-based nitric oxide reporter assay useful for the identification and characterization of modulators of the nitric oxide/guanosine 3',5'-cyclic monophosphate pathway. Wunder F; Buehler G; Hüser J; Mundt S; Bechem M; Kalthof B Anal Biochem; 2007 Apr; 363(2):219-27. PubMed ID: 17336915 [TBL] [Abstract][Full Text] [Related]
28. Conventional and Unconventional Mechanisms for Soluble Guanylyl Cyclase Signaling. Gao Y J Cardiovasc Pharmacol; 2016 May; 67(5):367-72. PubMed ID: 26452163 [TBL] [Abstract][Full Text] [Related]
29. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs. Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984 [TBL] [Abstract][Full Text] [Related]
30. The Endothelium-Dependent Nitric Oxide-cGMP Pathway. Mónica FZ; Bian K; Murad F Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093 [TBL] [Abstract][Full Text] [Related]
31. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. Breitenstein S; Roessig L; Sandner P; Lewis KS Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610 [TBL] [Abstract][Full Text] [Related]
32. The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis. Baldissera L; Squebola-Cola DM; Calixto MC; Lima-Barbosa AP; Rennó AL; Anhê GF; Condino-Neto A; De Nucci G; Antunes E Pulm Pharmacol Ther; 2016 Dec; 41():86-95. PubMed ID: 27816773 [TBL] [Abstract][Full Text] [Related]
34. The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2. Zhang S; Zou L; Yang T; Yang Y; Zhai Z; Xiao F; Wang C Exp Cell Res; 2015 Mar; 332(2):278-87. PubMed ID: 25704756 [TBL] [Abstract][Full Text] [Related]
35. Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma. Ghosh A; Koziol-White CJ; Asosingh K; Cheng G; Ruple L; Groneberg D; Friebe A; Comhair SA; Stasch JP; Panettieri RA; Aronica MA; Erzurum SC; Stuehr DJ Proc Natl Acad Sci U S A; 2016 Apr; 113(17):E2355-62. PubMed ID: 27071111 [TBL] [Abstract][Full Text] [Related]
37. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor. Füllhase C; Hennenberg M; Sandner P; Strittmatter F; Niedworok C; Bauer RM; Gratzke C; Soler R; Stief C; Andersson KE Neurourol Urodyn; 2015 Nov; 34(8):787-93. PubMed ID: 25230878 [TBL] [Abstract][Full Text] [Related]